These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3591453)

  • 41. Variable depletion of endogenous factor XII-dependent fibrinolytic activity following thrombolytic therapy of myocardial infarction and its relation to reinfarction.
    Kluft C; Munkvad S; Gram J; Jespersen J
    Agents Actions Suppl; 1992; 38 ( Pt 2)():299-304. PubMed ID: 1462835
    [No Abstract]   [Full Text] [Related]  

  • 42. In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species.
    Lijnen HR; Marafino BJ; Collen D
    Thromb Haemost; 1984 Dec; 52(3):308-10. PubMed ID: 6543405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
    Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of the fibrinolytic system in myocardial infarction].
    Moreno JA; Cornudella R; Gálvez M; Angós JA; Romero S; Gutiérrez M
    Sangre (Barc); 1994 Feb; 39(1):23-7. PubMed ID: 8197514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
    Thögersen AM; Jansson JH; Boman K; Nilsson TK; Weinehall L; Huhtasaari F; Hallmans G
    Circulation; 1998 Nov; 98(21):2241-7. PubMed ID: 9826309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit.
    Voss R; Matthias FR; Borkowski G; Reitz D
    Br J Haematol; 1990 May; 75(1):99-105. PubMed ID: 1695855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina.
    Gurfinkel E; Altman R; Scazziota A; Rouvier J; Mautner B
    Br Heart J; 1994 Feb; 71(2):151-5. PubMed ID: 8130023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
    Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K
    J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
    Saito M; Nakabayashi T; Iuchi K; Ishikawa T; Kaseno K; Yoshida T; Asakura H; Matsuda T
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):801-4. PubMed ID: 7507363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis.
    Sakata K; Miura F; Sugino H; Shinobe M; Shirotani M; Yoshida H; Mori N; Hoshino T; Takada A
    Am Heart J; 1996 Jan; 131(1):1-6. PubMed ID: 8553994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defective fibrinolysis in survivors of myocardial infarction.
    Johnson O; Mellbring G; Nilsson T
    Int J Cardiol; 1984 Sep; 6(3):380-2. PubMed ID: 6541197
    [No Abstract]   [Full Text] [Related]  

  • 53. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
    Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
    Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pulmonary blood flow regulates plasma tissue plasminogen activator concentrations in patients with congenital heart defects.
    Mishima A; Asano M; Saito T; Yamamoto S; Ukai T; Yoshitomi H; Matsumoto K; Manabe T
    J Thorac Cardiovasc Surg; 1997 Apr; 113(4):742-7. PubMed ID: 9104984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of the fibrinolytic system in acute myocardial infarction after a normal exercise test.
    Sakata K; Kurata C; Taguchi T; Hayashi H; Kobayashi A; Yamazaki N; Rydzewski A; Takada A
    Eur Heart J; 1989 Dec; 10(12):1118-22. PubMed ID: 2514101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.
    Nilsson IM; Ljungnér H; Tengborn L
    Br Med J (Clin Res Ed); 1985 May; 290(6480):1453-6. PubMed ID: 3922531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.